Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.48 |
| ▸ | ACHE | P22303 | 7/20 | 0.48 |
| ▸ | CNR1 | P21554 | 6/20 | 0.48 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517141 | 0.87 | CNR2 (0.45) | CNR2ACHECNR1F2RL3MAPT | |
| SCHEMBL29644071 | 0.87 | CNR2 (0.45) | CNR2ACHECNR1F2RL3MAPT | |
| SCHEMBL5381747 | 0.81 | F2RL3 (0.48) | CNR2ACHECNR1F2RL3MAPT | |
| SCHEMBL30284921 | 0.78 | CNR2 (0.38) | CNR2ACHECNR1F2RL3MAPT | |
| SCHEMBL2144335 | 0.78 | CNR2 (0.38) | CNR2ACHECNR1F2RL3MAPT | |
| SCHEMBL25925602 | 0.76 | CNR1 (0.44) | CNR2ACHECNR1MAPTF2 | |
| SCHEMBL29644016 | 0.76 | CNR2 (0.43) | CNR2ACHECNR1F2RL3MAPT | |
| SCHEMBL2470918 | 0.74 | CNR2 (0.45) | CNR2ACHECNR1F2RL3MAPT | |
| SCHEMBL19208718 | 0.74 | ELANE (0.49) | CNR2ACHECNR1MAPTF2 | |
| SCHEMBL30183407 | 0.74 | CNR2 (0.45) | CNR2ACHECNR1F2RL3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295413-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295412-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| CN-1812973-B | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2010-12-22 | — | — | CN | disclosed |
| CN-1812973-A | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICAL CO LTD (US) | 2006-08-02 | — | — | CN | disclosed |
| US-7041687-B2 | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1467972-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040009968-A1 | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-15 | — | — | US | disclosed |
| WO-2003064397-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009968-A1 | Indazole compounds useful as protein kinase inhibitors | PRKD3, PDPK1, PDK1 | CNR2 2766/4885ACHE 2333/4885CNR1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.